Trial · NCT05546320
Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale
NCT05546320, Phase 2, Completed, Chinese Academy of Medical Sciences, Fuwai Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale. Trials, record NCT05546320. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05546320
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale
- NCT number
- NCT05546320
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 1,000 participants, actual
- Lead sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Conditions
- Patent Foramen Ovale, Migraine
- Interventions
- Aspirin 300mg, Metoprolol 25mg, Clopidogrel 75mg, Rivaroxaban 20mg
- First posted
- 2022-09-19
- Last updated
- 2026-04-22
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Responder rate | Baseline to 12 weeks post-randomization | Defined as the proportion of participants achieving a ≥50% reduction in the mean number of monthly migraine days or migraine attacks at 12 weeks post-randomization compared to baseline. |
| Secondary | Change in monthly migraine days | Baseline to 12 weeks post-randomization | Change in the mean number of migraine days at 12 weeks post-randomization compared to baseline. |
| Secondary | Change in monthly migraine attacks | Baseline to 12 weeks post-randomization | Change in the mean number of migraine attacks at 12 weeks post-randomization compared to baseline. |
| Secondary | Reduction rate of migraine days | Baseline to 12 weeks post-randomization | Percentage reduction in the mean number of migraine days at 12 weeks post-randomization compared to baseline. |
| Secondary | Reduction rate of migraine attacks | Baseline to 12 weeks post-randomization | Percentage reduction in the mean number of migraine attacks at 12 weeks post-randomization compared to baseline. |
| Secondary | Complete migraine cessation | Weeks 9-12 post-randomization | Percentage of participants achieving complete migraine cessation during the 12-week treatment period. |
| Secondary | Migraine-specific quality of life (MSQ v2.1) | Baseline to 12 weeks post-randomization | Change in Migraine-Specific Quality of Life Questionnaire (MSQ version 2.1) scores at 12 weeks post-randomization compared to baseline. |
| Other | Safety Outcome Measures - Any adverse events | Baseline to 12 weeks post-randomization | Any undesirable medical condition occurring in a participant after initiation of the investigational medicinal products, regardless of its causal relationship with the investigational medicinal products, assessed by investigators and adjudicated by the clinical event committee. |
| Other | Safety Outcome Measures - Adverse events related to investigational medicinal products | Baseline to 12 weeks post-randomization | Adverse events assessed by investigators as having a definite, probable, or possible causal relationship with the investigational medicinal products, assessed by investigators and adjudicated by the clinical event committee. |
| Other | Safety Outcome Measures - Serious adverse events | Baseline to 12 weeks post-randomization | Events including death, life-threatening events, hospitalization or prolongation of hospitalization, permanent disability or damage, congenital anomaly or birth defect, or other medically significant events, assessed by investigators and adjudicated by the clinical event committee. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05546320
GET https://conductscience.org/api/trials/v1/NCT05546320/registered